NVX-CoV2373 (Novavax) was found to provide 100% protection against moderate and severe disease and 90.4% efficacy overall in a phase 3 trial last year.
NVX-CoV2373 (Novavax) is a recombinant nanoparticle protein-based COVID-19 vaccine that showed 100% protection against moderate and severe disease and 90.4% efficacy overall in the phase 3 PREVENT-19 trial.
The PREVENT-19 trial was a placebo-controlled, observer-blinded study, which was randomized 2:1. During the trial, investigators enrolled 29,960 people in the United States and Mexico to assess the efficacy, safety, and immunogenicity of the vaccine.
Data from the trial demonstrated that NVX-CoV2373 met its primary endpoint with an overall efficacy of 90.4% (95% CI: 82.9, 94.6). During the trial, 77 cases of COVID-19 were observed, with 63 in the placebo group and 14 in the vaccine group. The observed cases in the vaccine group were mild and in the placebo group there were 10 moderate cases and 4 severe cases observed, yielding a vaccine efficacy of 100% (95% CI: 87, 100) against moderate or severe disease.